Nick Uglem

ipa subsidiary biostrand receives grant to expand lensai platform by linking hyfts™ with 3d protein structure and function diepenbeek, (belgium), may 9, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to share that ipa’s subsidiary biostrand, a belgian end-to-end multi-omics analysis platform provider, has received a €460,000 round of grant funding from vlaio (flanders innovation & entrepreneurship), the research fund of the flemish regional government in belgium. conditionally awarded in january this year, biostrand recently satisfied the remaining criteria for the award, which follows an original grant from vlaio of €235,000 in 2020. commenting on the latest grant, dr. ingrid brands, general manager and co-founder of biostrand, stated, “thus far, our patented hyft™-based methodology has been applied predominantly to streamline analysis at the syntactic level and combines sequence information with natural language processing. using the presence, occurrence, and distribution of hyft™ patterns, the focus has been on analysis and integration of sequence-based ‘syntactical’ information. we are now extending the methodology to combine syntactical and structural information and to expand our services portfolio with hyft™-based structural and functional modelling functionalities. by linking hyfts™ with the 3d structure (and function) of proteins and expanding platform capabilities for ai discovery, we will be able to support an even wider array of applications, including assay development, biomarker discovery, and computer-aided drug design.” the strategic objective driving this hyft™-based synthesis of syntactical and structural information is to extend biostrand’s technology to encompass the structure of proteins. a key advantage of this blended approach is the detection of protein sequences with similar structures (and function) but without high sequence similarity (distant homologs). a primary application for this approach will be in protein structure prediction, with a particular first focus on antibodies as well as g protein coupled receptors (gpcrs). this will be extended to cover protein-protein interaction prediction (ppi) at a later stage. biostrand is also working on an ai discovery platform that will leverage advanced ai techniques to facilitate integrated protein structure and function analysis. combined with existing r&r and variant analyzer modules, natural language analysis capabilities and the hyft™-based unified syntactical plus structural methodology, biostrand’s ai discovery platform will empower researchers to fully analyse their data and gain insights across the entire analysis pipeline, from raw sequencing data to biologically relevant aspects such as diagnostics and drug discovery. the expansion of biostrand’s omics platform with these advanced functionalities is crucial to become an ambitious market player and position biostrand as a one-stop-shop for omics analysis,” said dr. brands. “we believe that integrating sequence and 3d structure analysis in combination with natural language processing will revolutionize protein structure and function prediction and boost developments in biotechnology and precision medicine. providing a powerful, integrated, and user-friendly data analysis platform for life sciences researchers is our contribution to ramping up the effectiveness of r&d cycles and enabling the real-time analysis of actionable patient data that will bring precision medicine to the next level. it also takes us one step further in our mission to create a truly effective omics data analysis solution.” the company also announces the departure of stefan lang, chief business officer of ipa, effective immediately, and wishes him the best in his future endeavors. immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors — to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. investor contact: email: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified using words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to complete the studies proposed for the grant award. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no, 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). furthermore, there can be no assurance that the pending patent applications will issue as patents and that challenges will not be instituted against the validity or enforceability of such patents. should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

• ipa’s polytope® tatx-03 shows continuous validation of potent in vitro neutralizing activity against sars-cov-2 variants of concern, as further demonstrated against the omicron sublineage ba.2 • neutralization potency of the tatx-03 cocktail towards ba.2-pseudotyped viral particles is comparable to its previously reported neutralizing activity against omicron ba.1 •in addition to retained potent neutralization by the cocktail as a whole, all four individual therapeutic antibodies in ipa’s tatx-03 retained binding to the ba.2 spike trimer, with reactivity profiles similar to ba.1 victoria, british columbia (canada), april 20, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to share the outcome of recent laboratory data on their polytope® tatx-03 antibody cocktail, which demonstrates strong neutralizing activity toward the omicron subvariant ba.2. the ba.2 pseudovirus was neutralized with a potency comparable to the previously analyzed omicron ba.1, demonstrating ongoing and continued consistency of the cocktail to potently neutralize sars-cov-2 variants of concern (voc). this functional outcome was supported by demonstrated binding of each individual antibody constituent to spike-protein trimer ba.2, data which is also highly comparable with the binding observed against ba.1. various sublineages were identified relatively soon after the sars-cov-2 omicron variant was designated as a voc. of the sublineages classified, ba.2 and ba.3 have higher transmission potential than, for example, ba.1. given the global prevalence and exceptional transmissibility of ba.2, as well as the reality that most antibody therapies authorized by the fda under emergency use authorization have lost neutralizing potency against the omicron variants, recent conversations with the food and drug administration led to prioritizing potency screening of ipa’s tatx-03 product toward ba.2. in line with recent in silico modelling predictions at ipa, the in vitro experimental data showed no significant difference in tatx-03 antibody binding to omicron and the ba.2 sublineage. as anticipated, ipa’s rationally designed anti-sars-cov-2 cocktail potently prevented cell infection by omicron sublineage ba.2 pseudovirus particles at similar antibody concentrations compared to ba.1, resulting in complete neutralization of this dominant subvariant. “in our news release on january 31st, we announced data demonstrating the potent neutralization of the omicron ba.1 subvariant by ipa’s polytope® tatx-03. once again, the remarkable and unprecedented endurance of our first-generation tatx-03 antibody cocktail demonstrates a unique ability to maintain neutralization potency against all concerning viral mutants, this time against the currently dominant omicron sublineage ba.2 containing, yet again, unique mutations,” stated dr. ilse roodink, cso of ipa. “with the new results on the ba.2 subvariant, the vast data package on ipa’s tatx-03 pharmaceutical continues to mount, demonstrating limited variation in its powerful and consistent neutralization potency against all virus variants, giving great confidence to the significance of this resilient product. this is, again, a wonderful confirmation of the sustainability and long-term value of our tatx-03 therapy.” immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors — to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. investor contact: lifesci advisors john mullaly email: jmullaly@lifesciadvisors.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to complete its pre-ind studies, the ability of the company to successfully submit an ind application with respect to polytope® tatx-03, statements regarding regulatory approvals, statements regarding the potential of ipa’s polytope® tatx-03 to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment (therapeutic), or to retain efficacy over time. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely completing its pre-ind studies or submitting an ind application to the fda, developing its polytope® monoclonal antibodies, including tatx-03, or other vaccines or therapeutics against covid-19 through the successful and timely completion of preclinical assays, studies and clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of its products, including polytope® tatx-03 and, be successful in partnering or commercializing its products related to covid-19, the coverage and applicability of the company’s intellectual property rights to its polytope® antibody cocktails, as well as those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no, 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). furthermore, there can be no assurance that the pending patent applications will issue as patents and that challenges will not be instituted against the validity or enforceability of such patents. should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

victoria, british columbia (canada), april 14, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to announce that it has completed its previously announced acquisition of control over biostrand bv, biokey bv, and bioclue bv (hereinafter collectively referred to as “biostrand“), a group of belgian biotech entities and pioneers in the field of bioinformatics and biotechnology, through its wholly owned subsidiary immunoprecise netherlands bv. “uniting biostrand and ipa reflects the company’s commitment to acquiring truly transformative technologies that leapfrog traditional competencies driving the development of safe and effective antibody therapies. for several years ipa’s team has scrutinized artificial intelligence (ai) and machine learning technologies, in search of capabilities that don’t simply give a nod to an opaque use of computationally-driven analyses, nor incremental and limited additions to currently existing research tools, but instead change the trajectory of personalized medicines and the philosophy behind what is truly meaningful for the future of ai in the life sciences,” commented dr. jennifer bath, ceo of ipa. “with biostrand joining the ipa family, we rewrite the future of biotherapeutic discovery, providing access to unique and rapid in silico technologies that unequivocally improve the specificity and design of biotherapeutics,” dr. bath continued. “this is achieved, in part, using patent-pending technologies that identify, define, and code finite and unique fingerprints representing structures and functions present in all omic data. together, we share a common vision and unique strengths using the power of rapidly analyzed genomic, transcriptomic, and proteomic data, combined with natural language processing, to understand the structural and functional basis of diseases, and to develop life-saving precision medicines. our combined capabilities move us closer to more precise and powerful individualized therapies with an aim of changing the way therapies are designed, approved, and prescribed.“ details of the transaction immunoprecise netherlands bv acquired all of the issued and outstanding shares of idea family bv, a private limited liability company holding 75.01% of the issued and outstanding shares of biostrand, as well as the remaining 24.99% of the issued and outstanding shares of biostrand. at closing, the company paid a consideration of approximately € 20 million to the vendors, namely charmquark een, a partnership (maatschap) controlled by dirk van hyfte, charmquark twee, a partnership (maatschap) controlled by ingrid brands, and k&e bv, a private limited liability company (besloten vennootschap) controlled by koen quaghebeur and els paesmans. the consideration consisted of an aggregate of 4,077,774 common shares of ipa, representing approximately € 16,265,500 based on the thirty-day volume-weighted average price of the common shares ending on the trading day immediately prior to the closing; and a cash payment of approximately € 3,734,500 the consideration also includes a contingent earnout payment based on the profitability of biostrand over a 7-year period, which shall not exceed in total €12 million. an investment consideration will also be provided by ipa to biostrand in an aggregate amount of € 6 million over a period of 3 years, for operation expenses, development of biostrand’s platform, and correction of deficiencies. the common shares issued are subject to a statutory resale restriction pursuant to canadian securities laws, as well as a contractual escrow agreement entered into on closing between the vendors, ipa, and an escrow agent, providing for the gradual release of the common shares over a 3-year period. each of biostrand and its securityholders are arm’s length parties to the company. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors— to optimize antibody discovery and development against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. about biostrand bv, biokey bv, and bioclue bv\ biostrand, biokey, and bioclue are private limited liability companies, incorporated under the laws of belgium, and are active in the field of bioinformatics and biotechnology. biostrand’s focus is on handling of biological sequences, and generating biological sequence information, software development, algorithms, data visualization and visual analytics. potential applications are in the field of molecular diagnostics, point of care testing, in depth analysis for drug development, prediction, construction and adaptation of biopolymer sequences as well as a product, service, or tool which stores this information in a database. the business of biokey is related to the identification of characteristic biological sequences in proteins, rna and dna, and their different information layers, the development of a knowledgebase containing these characteristic biological sequences and information layers, and the use of this database to process biological sequences and compare the processed biological sequences. bioclue focuses on technology for performing secondary analysis, consisting of read mapping / assembly and immediate identification of variations, as well as on products, services and tools related to the developed technology, primarily aimed at determining biological sequences in proteins, rna and dna, including through mass spectrometry, sequencing, microarray or hybrid microarray system technologies. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the launch of sequencing technologies and in silico discovery platforms and expectations regarding the impacts thereof, the contingent earn-out consideration, the form and use of the investment consideration provided by ipa to biostrand, expectations regarding synergies from the transaction and the ability to integrate biostrand into the company’s business, and the projected impact of completion of the transaction on the company’s business, financial conditions and results. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no. 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies investor contact lifesci advisors john mullaly email: jmullaly@lifesciadvisors.com

new platform integrates sequence data and information from entire biosphere • acquisition includes wholly owned subsidiary businesses biokey bv and bioclue bv. • platform is based on a proprietary biological discovery called hyft™ patterns, signature sequences in dna, rna, and amino acids. • the hyfts information model combined with advanced artificial intelligence (ai) creates new comprehensive high speed analysis capabilities while maintaining high accuracy and reducing computational footprint. • novel ai-powered protein-protein interactions prediction platform. victoria, british columbia (canada), march 29th, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to announce that it has entered into a definitive share purchase agreement (spa) to acquire, through its wholly-owned subsidiary immunoprecise netherlands bv, control over biostrand bv, biokey bv, and bioclue bv (hereinafter collectively referred to as “biostrand”), a group of belgian biotech entities and pioneers in the field of bioinformatics and biotechnology. this transaction is expected to create short and long-term commercialization opportunities with clients and partners by introducing a novel ai-powered protein-protein interactions prediction platform and fortifying ipa’s sequencing with massive throughput capabilities in omics (genomics, transcriptomics, proteomics, and metabolomics) interrogation. the company anticipates that the transaction will not only attract new clients and partners but will also enable its subsidiary, talem therapeutics, to access unparalleled ai technologies to help power each stage of its therapeutic antibody development. transaction highlights • biostrand offers a revolutionary, cloud-based solution to perform multi-omics research faster and more accurately, with more effective data analysis. • the acquisition enhances ipa’s position as a leader in the field of biotherapeutics – biostrand’s software and ai capabilities complement every sector of ipa’s business. • biostrand’s semantically driven natural language process (nlp) approach makes omics data research truly effective and differentiates ipa’s offerings to provide a powerful and unique opportunity for ipa’s clients. • total consideration of € 20 million, of which € 2 million will be paid in cash, subject to adjustments, and € 18 million will be paid in equity. • management and board of directors unanimously approved the transaction. differentiating technologies biostrand offers an ai-powered revolutionary methodology for rapidly analyzing and mining a broad range of biological data to identify patterns and variations in multi-omics data and detect structural anchor points that will drive innovation in numerous fields including precision medicine, drug and vaccine development, and target discovery. by detecting hyfts™, which are proprietary biological signature sequences, multiple layers of information in sequence and structural data are automatically integrated, resulting in a systems approach to omic analyses. these hyfttm fingerprints connect sequences and literature analysis through a bottom-up nlp approach, by providing a universal syntax for the language of biology. this revolutionizing pattern and profile detection is critical in understanding diseases and biological processes. multi-omics data integration typically requires quite considerable expertise in computational techniques with additional challenges in accuracy and reliability. with biostrand’s revolutionary hyft™ framework, all biological data is instantly computable. company synergies the acquisition of biostrand expands ipa’s scientific capabilities to excel far beyond antibody discovery, expanding from the earliest stages of target identification to late-stage therapies. the transaction combines biostrand’s computer-aided drug discovery capabilities with ipa’s best-in-class antibody discovery and development expertise to create an integrated, next-generation, end-to-end platform for target and therapeutic antibody discovery and development. dr. jennifer bath, president and chief executive officer of immunoprecise antibodies, commented, “the addition of biostrand’s next-generation capabilities in systems omics analysis further enhances ipa’s unique ability to serve as a single-source partner to support our clients’ in silico, in vitro and in vivo research, further solidifying our position as the leading, early-stage antibody discovery contract research organization. a previously undisclosed collaboration with biostrand has already generated unique and intriguing data and we are confident that our clients and partners will find the addition of biostrand’s offerings both advantageous and transformational for their research programs. we believe the acquisition of biostrand, recently referred to as the “google of genomics”, is a blockbuster move, brings together a revolutionary combination that will change the way researchers approach and complete target and antibody discovery, and that our combined platforms, once integrated, will attract new business opportunities at an accelerated rate. we are excited to add biostrand to the ipa family.” the transaction pursuant to the spa, immunoprecise netherlands b.v. will acquire i) all of the issued and outstanding shares of idea family bv, a private limited liability company holding 75.01% of the issued and outstanding shares of biostrand and ii) the remaining 24.99% of the issued and outstanding shares of biostrand, the whole for a total consideration of approximately € 20 million, plus a potential earnout consideration. the purchase price will be satisfied as follows: • approximately € 2 million payable in cash, of which € 1 million will be subject to holdback. a sum of € 500,000 will be held back for a period of 90 days after closing of the transaction for adjustment purposes and € 500,000 of the cash consideration will be held back and progressively released over a 3-year period to guarantee the obligations of the vendors under the spa; • a number of common shares of ipa to be issued at closing, the value per common share to be determined based on the 30-day volume-weighted average price of the common shares (vwap) ending on the trading day immediately prior to the date of closing, representing no greater than 19.99% of the issued and outstanding common shares of ipa immediately prior to closing, for an aggregate deemed value of € 18 million. in the event the issuance cap is reached, ipa will make a cash payment to the vendors equal to the value of the common shares that were not issued as a result of the issuance cap, based on the vwap of the common shares as of the closing date; and • a contingent earnout payment based on the profitability of biostrand over a 7-year period, which shall not exceed in total € 12 million. other key deal terms • biostrand is being acquired on a debt-free, cash-free basis; • investment consideration provided by ipa to biostrand of aggregate amount of € 6 million in the form of a loan or in the form of equity over a period of 3 years for operation expenses, development of biostrand’s platform, and correction of deficiencies; • customary representations and warranties in the spa; • customary indemnities for breaches of representations and warranties and breaches of covenants in the spa; • the equity consideration will be subject to a 4-month statutory resale restriction period pursuant to canadian securities laws, as well as a contractual escrow agreement to be entered into at closing between the vendors, ipa, and an escrow agent, providing for the gradual release of the common shares over a 3-year period. • key personnel, including the founders of biostrand and other members of the executive team of biostrand, will continue their employment with updated management agreements; • non-competition and non-solicitation agreements will be entered into, as a condition of closing, with certain principals of biostrand; • each of biostrand and the biostrand shareholders are arm’s length parties to the company; • the purchase price is subject to working capital and other adjustments; • closing of the transaction is expected to occur on or before april 15, 2022, subject to receipt of all applicable approvals and the satisfaction of applicable conditions to closing; • the other closing conditions in the spa are customary, including, but not limited to, the receipt of all necessary regulatory approvals and the required notifications to nasdaq with respect to the issuance of ipa’s common shares; and • the transaction is an “expedited acquisition” under policy 5.3 of the tsx venture exchange. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors— to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. about biostrand bv biostrand bv is a private limited liability company, incorporated under the laws of belgium. the business of biostrand bv focuses on technology, in the field of bioinformatics and biotechnology, for handling of biological sequences including for example processing, storing and comparing biological sequence information, and for generating biological sequence information, software development, algorithms, data visualisation and visual analytics, which can for example be applied in the field of molecular diagnostics, point of care testing, in depth analysis for drug development, prediction, construction and adaptation of biopolymer sequences as well as a product, service, or tool which stores this information in a database. about biokey bv biokey bv is a private limited liability company, incorporated under the laws of belgium. the business of biokey bv focuses on technology, in the field of bioinformatics and biotechnology, related to the identification of characteristic biological sequences in proteins, rna and dna, and their different information layers, the development of a knowledgebase containing these characteristic biological sequences and information layers, and the use of this database to process biological sequences and compare the processed biological sequences. about bioclue bv bioclue bv is a private limited liability company, incorporated under the laws of belgium. the business of bioclue bv focuses on technology, in the field of bioinformatics and biotechnology, for performing, inherently linked with a microarray process and possible primary analysis, a secondary analysis, whether or not performed simultaneously with the primary analysis, consisting of read mapping, read assembly – de novo or reference based – and immediate identification of variations, as well as on products, services and tools related to the developed technology, primarily aimed at determining biological sequences in proteins, rna and dna, including through mass spectrometry, sequencing, micro array or hybrid microarray system technologies. investor contact: lifesci advisors john mullaly email: jmullaly@lifesciadvisors.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the transaction, expectations regarding synergies from the transaction and the ability to integrate biostrand into the company’s business, pro forma financial estimates, including revenue, the opportunities presented by the transaction, synergies and expansion opportunities, the expansion of the company’s knowledge lifecycle, the expected closing of the transaction, the receipt of all necessary regulatory approvals and satisfaction of all other closing conditions and the projected impact of completion of the transaction on the company’s business, financial conditions and results. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely completing the transaction, the necessary approvals are not obtained or some other condition to the closing of the transaction is not satisfied, as well as those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no. 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. there is no guarantee that the transaction will close at all, or in the time frame anticipated, or on the terms as originally negotiated. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies